AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15722809 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 133
Study 15722809 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use
Number of subjects: 133
Study 15722809 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mean VAS scores
Number of subjects: 133
Study 15722809 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal VAS score
Number of subjects: 133
Study 11973381 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite solution I (amphipathic lipids)
Number of subjects: 20
Study 11973381 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite solution II (amphipathic lipids)
Number of subjects: 20
Study 11973381 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral eye treated with no intervention)
Number of subjects: 20
Study 9433341 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dextroamphetamine challenge
Number of subjects: 34
Study 9433341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8133112 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescent antibody (IFA) test for detection of Babesia microti antibody
Number of subjects: 130
Study 2804996 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 6
Study 2804996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 797057 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication
Number of subjects: 110
Study 797057 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychic conditioning
Number of subjects: 110
Study 797057 — intervention group
Group type: COMPARATOR
Intervention: Dental procedures (extraction, filling therapy, prosthodontic procedures)
Number of subjects: 110
Study 7315832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphygmetrics SR-2 Automatic Blood Pressure Recorder
Number of subjects: 71
Study 7315832 — intervention group
Group type: COMPARATOR
Intervention: Auscultation using a biaural stethoscope and mercury sphygmomanometer
Number of subjects: 71
Study 31992394 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 10
Study 31992394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30657023 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring delivering the antiretroviral dapivirine
Number of subjects: 214
Study 30657023 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant engagement activities
Number of subjects: 214
Study 28445659 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (20 mg or 40 mg according to body weight, administered subcutaneously every 2 weeks)
Number of subjects: 90
Study 28445659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered subcutaneously every 2 weeks)
Number of subjects: 90
Study 28445659 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 90
Study 28445659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25537159 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (50 mg daily)
Number of subjects: 29
Study 25537159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg daily)
Number of subjects: 29
Study 25537159 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (4 mg/kg loading dose, then 2 mg/kg/week)
Number of subjects: 29
Study 25537159 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 29
Study 25537159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 29
Study 25537159 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 29
Study 24345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor activities ≤9.0 hours/week
Number of subjects: 469
Study 24345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor activities >9.0 hours/week
Number of subjects: 469
Study 24345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nearwork activity >21.0 hours/week
Number of subjects: 469
Study 24345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nearwork activity ≤21.0 hours/week
Number of subjects: 469
Study 24345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline nearwork as a continuous variable
Number of subjects: 469
Study 21776572 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee arthroplasty
Number of subjects: 113
Study 21776572 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 113
Study 19556536 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 U/kg of recombinant human erythropoietin
Number of subjects: 32
Study 19556536 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 U/kg of recombinant human erythropoietin
Number of subjects: 32
Study 19556536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 U/kg of recombinant human erythropoietin
Number of subjects: 32
Study 19556536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19556536 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin at any dose
Number of subjects: 32
Study 17492951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous FFA infusion (intralipid/heparin infusion 4 h)
Number of subjects: 8
Study 17492951 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration (0.5 mg i.v.)
Number of subjects: 8
Study 17492951 — intervention group
Group type: EXPERIMENTAL
Intervention: GHR blockade (pegvisomant, 30 mg s.c.)
Number of subjects: 8
Study 17492951 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 8
Study 15352967 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g)
Number of subjects: 71
Study 15352967 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg)
Number of subjects: 71
Study 15352967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Propacetamol (2 g) and Diclofenac (75 mg)
Number of subjects: 71
Study 15352967 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study 12029287 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 24
Study 12029287 — intervention group
Group type: COMPARATOR
Intervention: 0.75% ropivacaine
Number of subjects: 24
Study 12029287 — intervention group
Group type: COMPARATOR
Intervention: 1% ropivacaine
Number of subjects: 24
Study 9828851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 750 micrograms/day
Number of subjects: 30
Study 9828851 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 1500 micrograms/day
Number of subjects: 30
Study 7859697 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-based food frequency questionnaire (FFQ) format 1
Number of subjects: 651
Study 7859697 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-based food frequency questionnaire (FFQ) format 2
Number of subjects: 651
Study 7859697 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-based food frequency questionnaire (FFQ) format 3
Number of subjects: 651
Study 7859697 — intervention group
Group type: EXPERIMENTAL
Intervention: FFQ completed after 4-6 weeks
Number of subjects: 651
Study 7859697 — intervention group
Group type: EXPERIMENTAL
Intervention: FFQ completed after 3 months
Number of subjects: 651
Study 2696983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Number of subjects: 29
Study 2696983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (informed group)
Number of subjects: 29
Study 2696983 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 29
Study 1089446 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg daily
Number of subjects: 40
Study 1089446 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg three times a week
Number of subjects: 40
Study 30949710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 17
Study 28929249 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon-initiated photoacoustic streaming (PIPS)
Number of subjects: 36
Study 28929249 — intervention group
Group type: COMPARATOR
Intervention: Rotary phase of retreatment
Number of subjects: 36
Study 26508753 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU)
Number of subjects: 26
Study 26508753 — intervention group
Group type: COMPARATOR
Intervention: Standard Management (SM)
Number of subjects: 26
Study 24262217 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Syndromic Management (ESM)
Number of subjects: 549
Study 24262217 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic Presumptive Treatment (PPT)
Number of subjects: 549
Study 24262217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ESM and PPT
Number of subjects: 549
Study 21254853 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 104
Study 21254853 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (TCS)
Number of subjects: 104
Study 20384182 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ataxia-telangiectasia syndrome (AT)
Number of subjects: 46
Study 20384182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group of children with AT (males and females)
Number of subjects: 46
Study 17532774 — intervention group
Group type: EXPERIMENTAL
Intervention: RinsEndo-system; 5‐mL NaOCl, 50 s
Number of subjects: 45
Study 17532774 — intervention group
Group type: COMPARATOR
Intervention: Flushing with a syringe; 5‐mL NaOCl, 1 min
Number of subjects: 45
Study 17532774 — intervention group
Group type: COMPARATOR
Intervention: Static application of irrigant; 3 min
Number of subjects: 45
Study 17532774 — intervention group
Group type: EXPERIMENTAL
Intervention: RinsEndo-system
Number of subjects: 45
Study 17532774 — intervention group
Group type: COMPARATOR
Intervention: Static application/flushing with a syringe
Number of subjects: 45
Study 15201658 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA‐ME
Number of subjects: 495
Study 15201658 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 495
Study 11952508 — intervention group
Group type: EXPERIMENTAL
Intervention: IVAA 500 mg twice weekly for 8 weeks
Number of subjects: 36
Study 11952508 — intervention group
Group type: EXPERIMENTAL
Intervention: IVAA 500 mg/week for 8 weeks (Group 1)
Number of subjects: 36
Study 11952508 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Group 2)
Number of subjects: 36
Study 11952508 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial phase IVAA treatment
Number of subjects: 36
Study 9811084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 1726
Study 9811084 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation (TSF)
Number of subjects: 1726
Study 9811084 — intervention group
Group type: COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 1726
Study 7808063 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative food frequency questionnaire
Number of subjects: 155
Study 7808063 — intervention group
Group type: COMPARATOR
Intervention: 24-hour recall
Number of subjects: 155
Study 7808063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 155
Study 2759127 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-MDP
Number of subjects: 237
Study 2759127 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-DPD
Number of subjects: 237
Study 2759127 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological examination
Number of subjects: 237
Study 266313 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy consisting of cytarabine and 6-thioguanine for two days each month
Number of subjects: 26
Study 266313 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 26
Study 30247454 — intervention group
Group type: EXPERIMENTAL
Intervention: Broselow tape
Number of subjects: 40
Study 31106998 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen addition (FN)
Number of subjects: 18
Study 31106998 — intervention group
Group type: COMPARATOR
Intervention: Sterilization (FS)
Number of subjects: 18
Study 31106998 — intervention group
Group type: COMPARATOR
Intervention: Sterilization and nitrogen addition (FSN)
Number of subjects: 18
Study 31106998 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (F)
Number of subjects: 18
Study 27753684 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide plus Darunavir (E/C/F/TAF + DRV)
Number of subjects: 135
Study 27753684 — intervention group
Group type: COMPARATOR
Intervention: Baseline regimen
Number of subjects: 135
Study 25020153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed video
Number of subjects: 855
Study 25020153 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed video
Number of subjects: 855
Study 25020153 — intervention group
Group type: COMPARATOR
Intervention: No health message
Number of subjects: 855
Study 23389782 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIGEN INTERTAN nail
Number of subjects: 684
Study 23389782 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 684
Study 21150914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous THC (1.25 mg)
Number of subjects: 16
Study 21150914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19645039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 240
Study 19645039 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study 17917830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural fluid (PF) VEGF levels
Number of subjects: 113
Study 17917830 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum VEGF levels
Number of subjects: 113
Study 17917830 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for PF VEGF
Number of subjects: 113
Study 17917830 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for serum VEGF
Number of subjects: 113
Study 17917830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascade connection and parallel operation of PF and serum VEGF
Number of subjects: 113
Study 15499961 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction rule based on nine independent risk factors (gender, birthweight, educational level of the father, S. pneumoniae, cerebrospinal fluid leukocyte count, delay between admission and start of antibiotics, dexamethasone use, seizures treated with anticonvulsive therapy, prolonged fever)
Number of subjects: 182
Study 15499961 — intervention group
Group type: COMPARATOR
Intervention: Cohort of children who survived bacterial meningitis
Number of subjects: 182
Study 15499961 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score computed using the prediction rule
Number of subjects: 182
Study 11180763 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (neoadjuvant chemotherapy)
Number of subjects: 0
Study 9131311 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1.0 mg/kg/day)
Number of subjects: 12
Study 9131311 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1.0 mg/kg/day) plus Metolazone (0.2 mg/kg/day)
Number of subjects: 12
Study 8482455 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous drainage
Number of subjects: 33
Study 8482455 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (10 mg.kg‐1.day‐1 for 8 weeks)
Number of subjects: 33
Study 8482455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of percutaneous drainage and albendazole
Number of subjects: 33
Study 8482455 — intervention group
Group type: COMPARATOR
Intervention: Albendazole alone
Number of subjects: 33
Study 3436158 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g aztreonam
Number of subjects: 225
Study 3436158 — intervention group
Group type: COMPARATOR
Intervention: 2.4 mega units procaine penicillin plus 1 g probenacid
Number of subjects: 225
Study 30630797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-driven aerosol (Group A)
Number of subjects: 180
Study 30630797 — intervention group
Group type: COMPARATOR
Intervention: Air compressor-driven aerosol (Group B)
Number of subjects: 180
Study 25483417 — intervention group
Group type: EXPERIMENTAL
Intervention: Single loading dose only
Number of subjects: 240
Study 25483417 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h abbreviated protocol
Number of subjects: 240
Study 25483417 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h standard protocol
Number of subjects: 240
Study 25483417 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 240
Study 23143081 — intervention group
Group type: EXPERIMENTAL
Intervention: External coaching targeting social climate (3 post-training booster sessions)
Number of subjects: 231
Study 23143081 — intervention group
Group type: EXPERIMENTAL
Intervention: External coaching targeting skills and knowledge (3 post-training booster sessions)
Number of subjects: 231
Study 23143081 — intervention group
Group type: COMPARATOR
Intervention: Management directives (control condition)
Number of subjects: 231
Study 23143081 — intervention group
Group type: EXPERIMENTAL
Intervention: Social climate coaching
Number of subjects: 231
Study 22317882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N-butylbromide (1 mL, 20 mg IV)
Number of subjects: 674
Study 22317882 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl solution)
Number of subjects: 674
Study 20047622 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)-based therapy
Number of subjects: 0
Study 20047622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17207103 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step treatment program
Number of subjects: 887
Study 17207103 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment program
Number of subjects: 887
Study 16054329 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen integrated in 24-hour care
Number of subjects: 250
Study 16054329 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 250
Study 12823777 — intervention group
Group type: EXPERIMENTAL
Intervention: Purine analogs (fludarabine, 2‐chlorodeoxyadenosine, pentostatin)
Number of subjects: 0
Study 12823777 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies (rituximab, alemtuzumab)
Number of subjects: 0
Study 12823777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of antibodies with chemotherapy
Number of subjects: 0
Study 12823777 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies and transplantation (autologous and allogeneic)
Number of subjects: 0
Study 9929086 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured aerobic exercise
Number of subjects: 40
Study 9929086 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate lifestyle activity
Number of subjects: 40
Study 8522226 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol at a rising dose of 2 to 8 mg, totaling 16 mg over 20 days
Number of subjects: 50
Study 8522226 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal estriol 0.03 mg/day for 10 days and 0.06 mg/day for 10 days
Number of subjects: 50
Study 1415824 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day of alprazolam
Number of subjects: 96
Study 1415824 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/day of alprazolam
Number of subjects: 96
Study 1415824 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day or 6 mg/day of alprazolam
Number of subjects: 96
Study 1415824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 3922207 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release nitroglycerin
Number of subjects: 9
Study 3922207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3922207 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem added to placebo
Number of subjects: 9
Study 3922207 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem added to nitroglycerin
Number of subjects: 9
Study 3922207 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nitroglycerin and diltiazem
Number of subjects: 9
Study 30458734 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA exponential decrease group (0.9 < R2 ≤ 1.0)
Number of subjects: 146
Study 30458734 — intervention group
Group type: COMPARATOR
Intervention: Non-exponential decrease group (R2 ≤ 0.9)
Number of subjects: 146
Study 27323444 — intervention group
Group type: EXPERIMENTAL
Intervention: deqi-expectation + sharp pain
Number of subjects: 87
Study 27323444 — intervention group
Group type: EXPERIMENTAL
Intervention: deqi-expectation + no-sharp pain
Number of subjects: 87
Study 27323444 — intervention group
Group type: EXPERIMENTAL
Intervention: no-deqi-expectation + sharp pain
Number of subjects: 87
Study 27323444 — intervention group
Group type: EXPERIMENTAL
Intervention: no-deqi-expectation + no-sharp pain
Number of subjects: 87
Study 26513939 — intervention group
Group type: EXPERIMENTAL
Intervention: OHE kits and 0.05% NaF mouth rinse and brushing instructions
Number of subjects: 75
Study 26513939 — intervention group
Group type: EXPERIMENTAL
Intervention: OHE kits and brushing instructions
Number of subjects: 75
Study 26513939 — intervention group
Group type: COMPARATOR
Intervention: Brushing instructions (Control)
Number of subjects: 75
Study 23530575 — intervention group
Group type: EXPERIMENTAL
Intervention: Enclomiphene citrate
Number of subjects: 12
Study 23530575 — intervention group
Group type: COMPARATOR
Intervention: Testosterone gel
Number of subjects: 12
Study 21378596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support provided to less critically ill infants during the first 3 weeks of life
Number of subjects: 1366
Study 21378596 — intervention group
Group type: COMPARATOR
Intervention: Nutritional support provided to more critically ill infants during the first 3 weeks of life
Number of subjects: 1366
Study 21378596 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daily energy intake during the first week of life
Number of subjects: 1366
Study 21378596 — intervention group
Group type: EXPERIMENTAL
Intervention: Rates of necrotizing enterocolitis
Number of subjects: 1366